Academic Journal

Identifying individuals at risk of needing CKD associated medications in a European kidney disease cohort

التفاصيل البيبلوغرافية
العنوان: Identifying individuals at risk of needing CKD associated medications in a European kidney disease cohort
المؤلفون: Eleni Stamellou, Turgay Saritas, Marc Froissart, Florian Kronenberg, Peter Stenvinkel, David C. Wheeler, Kai-Uwe Eckardt, Jürgen Floege, James Fotheringham
المصدر: BMC Nephrology, Vol 25, Iss 1, Pp 1-9 (2024)
بيانات النشر: BMC, 2024.
سنة النشر: 2024
المجموعة: LCC:Diseases of the genitourinary system. Urology
مصطلحات موضوعية: CKD G4/G5, CKD-MBD, Renal anemia, ESAs, VDRA, Phosphate binders, Diseases of the genitourinary system. Urology, RC870-923
الوصف: Abstract Background The consequences of chronic kidney disease (CKD) can be addressed with a range of pharmacotherapies primarily prescribed by nephrologists. More accurate information regarding future CKD-related pharmacotherapy requirements could guide clinical decisions including follow-up frequency. Methods Following assignment to derivation and validation groups (2,1), variables predicting individually future use of vitamin D receptor agonists (VDRA), phosphate binders, erythropoiesis stimulating agents (ESAs) and iron were identified using logistic regression in a prospective cohort study containing demography, comorbidity, hospitalization, laboratory, and mortality data in patients with CKD stage G4/G5 across six European countries. Discriminative ability was measured using C-statistics, and predicted probability of medication use used to inform follow-up frequency. Results A total of 2196 patients were included in the analysis. During a median follow-up of 735 days 648 initiated hemodialysis and 1548 did not. Combinations of age, diabetes status and iPTH, calcium, hemoglobin and serum albumin levels predicted the use of ESA, iron, phosphate binder or VDRA, with C-statistics of 0.70, 0.64, 0.73 and 0.63 in derivation cohorts respectively. Model performance in validation cohorts were similar. Sixteen percent of patients were predicted to have a likelihood of receiving any of these medications of less than 20%. Conclusions In a multi-country CKD cohort, prediction of ESA and phosphate binder use over a two-year period can be made based on patient characteristics with the potential to reduce frequency of follow-up in individuals with low risk for requiring these medications.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1471-2369
38736438
Relation: https://doaj.org/toc/1471-2369
DOI: 10.1186/s12882-024-03497-y
URL الوصول: https://doaj.org/article/17720dd38736438e84f2e30296ffc31c
رقم الانضمام: edsdoj.17720dd38736438e84f2e30296ffc31c
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:14712369
38736438
DOI:10.1186/s12882-024-03497-y